Lupin stands tall in digital therapeutics as others struggle

Lupin

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

While many digital therapeutics startups have folded or sold out under pressure, Lupin Digital Health has quietly built India’s most resilient platform, backed by clinical evidence, hospital partnerships, and physician prescriptions.

Launched in 2022, Lupin’s flagship platform LYFE is India’s first CDSCO-approved Class C software medical device for cardiac care. Unlike competitors that rushed to market, Lupin spent its early years conducting trials and publishing peer-reviewed studies — a strategy that CEO Sidharth Srinivasan says has been key to survival.

“You can’t just say, ‘trust me, bro.’ You have to generate evidence,” Srinivasan told Moneycontrol. “We’ve done over 15 publications and proved that LYFE users show statistically significant improvements in blood pressure, cholesterol, and hospital readmissions.”

Even large pharma companies like Cipla and Dr Reddy's struggled to make inroads into digital therapeutics.

Digital therapeutics (DTx) are software-based interventions that deliver evidence-based therapeutic outcomes for patients. Unlike wellness apps, DTx platforms are clinically validated and often regulated as medical devices. They are used to prevent, manage, or treat chronic conditions such as diabetes, heart failure, and obesity — often complementing traditional care.

Lupin’s LYFE platform is prescribed by over 1,000 cardiologists and used in more than 60 hospitals across India. The company has also launched VITALYFE on Thursday, an AI-powered cardiometabolic wellness platform aimed at India’s workforce, integrating features like heart age tracking, photo-based nutrition logging, and camera-guided exercise.

“We’re not just a tech company. We’re a healthcare company using tech,” Srinivasan said. “Doctors trust us because we’ve earned it — not because we’re backed by Lupin.”

While many players exited the space due to lack of scale or investor patience, Lupin Digital Health has managed to maintain positive unit economics. The company is now expanding into metabolic conditions like diabetes and obesity, and partnering with insurers to reduce lifestyle-related claims.

“We’re creating a market where none existed,” Srinivasan said. “It’s tough, but we’ve cracked the model — and we’re here to stay,” he added.